|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:GSTT1-CYP3A5 (FusionGDB2 ID:35019) |
Fusion Gene Summary for GSTT1-CYP3A5 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: GSTT1-CYP3A5 | Fusion gene ID: 35019 | Hgene | Tgene | Gene symbol | GSTT1 | CYP3A5 | Gene ID | 2952 | 1577 |
| Gene name | glutathione S-transferase theta 1 | cytochrome P450 family 3 subfamily A member 5 | |
| Synonyms | - | CP35|CYPIIIA5|P450PCN3|PCN3 | |
| Cytomap | 22q11.23 | 7q22.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | glutathione S-transferase theta-1GST class-theta-1glutathione transferase T1-1 | cytochrome P450 3A5aryl hydrocarbon hydroxylasecytochrome P450 HLp2cytochrome P450, family 3, subfamily A, polypeptide 5cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5cytochrome P450-PCN3flavoprotein-linked monooxygenasemicroso | |
| Modification date | 20200315 | 20200320 | |
| UniProtAcc | . | P20815 | |
| Ensembl transtripts involved in fusion gene | ENST00000248935, ENST00000439996, | ENST00000222982, ENST00000343703, ENST00000339843, ENST00000480723, ENST00000439761, | |
| Fusion gene scores | * DoF score | 4 X 2 X 3=24 | 8 X 5 X 4=160 |
| # samples | 3 | 9 | |
| ** MAII score | log2(3/24*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(9/160*10)=-0.830074998557688 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: GSTT1 [Title/Abstract] AND CYP3A5 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | GSTT1(24381700)-CYP3A5(99250402), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | GSTT1-CYP3A5 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. GSTT1-CYP3A5 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. GSTT1-CYP3A5 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | GSTT1 | GO:0006749 | glutathione metabolic process | 9307035|9434735|20097269 |
| Tgene | CYP3A5 | GO:0002933 | lipid hydroxylation | 14559847 |
| Tgene | CYP3A5 | GO:0008202 | steroid metabolic process | 14559847 |
| Tgene | CYP3A5 | GO:0008210 | estrogen metabolic process | 12865317 |
| Tgene | CYP3A5 | GO:0009822 | alkaloid catabolic process | 15039299 |
| Tgene | CYP3A5 | GO:0042573 | retinoic acid metabolic process | 11093772 |
| Tgene | CYP3A5 | GO:0042737 | drug catabolic process | 15039299 |
| Tgene | CYP3A5 | GO:0070989 | oxidative demethylation | 15039299 |
| Fusion gene breakpoints across GSTT1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CYP3A5 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | Non-Cancer | TCGA-CG-5733-11A | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
Top |
Fusion Gene ORF analysis for GSTT1-CYP3A5 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000248935 | ENST00000222982 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| Frame-shift | ENST00000248935 | ENST00000343703 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| 5CDS-3UTR | ENST00000248935 | ENST00000339843 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| 5CDS-intron | ENST00000248935 | ENST00000480723 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| 5CDS-intron | ENST00000248935 | ENST00000439761 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| intron-3CDS | ENST00000439996 | ENST00000222982 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| intron-3CDS | ENST00000439996 | ENST00000343703 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| intron-3UTR | ENST00000439996 | ENST00000339843 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| intron-intron | ENST00000439996 | ENST00000480723 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| intron-intron | ENST00000439996 | ENST00000439761 | GSTT1 | chr22 | 24381700 | - | CYP3A5 | chr7 | 99250402 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for GSTT1-CYP3A5 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for GSTT1-CYP3A5 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | CYP3A5 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:2732228, PubMed:10681376, PubMed:11093772, PubMed:12865317). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:2732228, PubMed:10681376, PubMed:11093772). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228). {ECO:0000269|PubMed:10681376, ECO:0000269|PubMed:11093772, ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:2732228}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for GSTT1-CYP3A5 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for GSTT1-CYP3A5 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for GSTT1-CYP3A5 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | CYP3A5 | P20815 | DB09061 | Cannabidiol | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for GSTT1-CYP3A5 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | GSTT1 | C0036341 | Schizophrenia | 5 | PSYGENET |
| Hgene | GSTT1 | C0033578 | Prostatic Neoplasms | 4 | CTD_human |
| Hgene | GSTT1 | C0376358 | Malignant neoplasm of prostate | 4 | CTD_human |
| Hgene | GSTT1 | C0004403 | Autosome Abnormalities | 3 | CTD_human |
| Hgene | GSTT1 | C0008625 | Chromosome Aberrations | 3 | CTD_human |
| Hgene | GSTT1 | C0019193 | Hepatitis, Toxic | 3 | CTD_human |
| Hgene | GSTT1 | C0860207 | Drug-Induced Liver Disease | 3 | CTD_human |
| Hgene | GSTT1 | C1262760 | Hepatitis, Drug-Induced | 3 | CTD_human |
| Hgene | GSTT1 | C3658290 | Drug-Induced Acute Liver Injury | 3 | CTD_human |
| Hgene | GSTT1 | C4277682 | Chemical and Drug Induced Liver Injury | 3 | CTD_human |
| Hgene | GSTT1 | C4279912 | Chemically-Induced Liver Toxicity | 3 | CTD_human |
| Hgene | GSTT1 | C0007134 | Renal Cell Carcinoma | 2 | CTD_human |
| Hgene | GSTT1 | C0236733 | Amphetamine-Related Disorders | 2 | CTD_human |
| Hgene | GSTT1 | C0236804 | Amphetamine Addiction | 2 | CTD_human |
| Hgene | GSTT1 | C0236807 | Amphetamine Abuse | 2 | CTD_human |
| Hgene | GSTT1 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 2 | CTD_human |
| Hgene | GSTT1 | C1266042 | Chromophobe Renal Cell Carcinoma | 2 | CTD_human |
| Hgene | GSTT1 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 2 | CTD_human |
| Hgene | GSTT1 | C1266044 | Collecting Duct Carcinoma of the Kidney | 2 | CTD_human |
| Hgene | GSTT1 | C1306837 | Papillary Renal Cell Carcinoma | 2 | CTD_human |
| Hgene | GSTT1 | C0003949 | Asbestosis | 1 | CTD_human |
| Hgene | GSTT1 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
| Hgene | GSTT1 | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| Hgene | GSTT1 | C0007097 | Carcinoma | 1 | CTD_human |
| Hgene | GSTT1 | C0007114 | Malignant neoplasm of skin | 1 | CTD_human |
| Hgene | GSTT1 | C0011570 | Mental Depression | 1 | PSYGENET |
| Hgene | GSTT1 | C0011581 | Depressive disorder | 1 | PSYGENET |
| Hgene | GSTT1 | C0017636 | Glioblastoma | 1 | CTD_human |
| Hgene | GSTT1 | C0020538 | Hypertensive disease | 1 | CTD_human |
| Hgene | GSTT1 | C0022665 | Kidney Neoplasm | 1 | CTD_human |
| Hgene | GSTT1 | C0024121 | Lung Neoplasms | 1 | CTD_human |
| Hgene | GSTT1 | C0026764 | Multiple Myeloma | 1 | CTD_human |
| Hgene | GSTT1 | C0027651 | Neoplasms | 1 | CTD_human |
| Hgene | GSTT1 | C0034734 | Raynaud Disease | 1 | CTD_human |
| Hgene | GSTT1 | C0034735 | Raynaud Phenomenon | 1 | CTD_human |
| Hgene | GSTT1 | C0037286 | Skin Neoplasms | 1 | CTD_human |
| Hgene | GSTT1 | C0086692 | Benign Neoplasm | 1 | CTD_human |
| Hgene | GSTT1 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| Hgene | GSTT1 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| Hgene | GSTT1 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| Hgene | GSTT1 | C0205699 | Carcinomatosis | 1 | CTD_human |
| Hgene | GSTT1 | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
| Hgene | GSTT1 | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human |
| Hgene | GSTT1 | C0334588 | Giant Cell Glioblastoma | 1 | CTD_human |
| Hgene | GSTT1 | C0400966 | Non-alcoholic Fatty Liver Disease | 1 | CTD_human |
| Hgene | GSTT1 | C0403823 | Asthenozoospermia | 1 | CTD_human |
| Hgene | GSTT1 | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human |
| Hgene | GSTT1 | C1449861 | Micronuclei, Chromosome-Defective | 1 | CTD_human |
| Hgene | GSTT1 | C1449862 | Micronuclei, Genotoxicant-Induced | 1 | CTD_human |
| Hgene | GSTT1 | C1621958 | Glioblastoma Multiforme | 1 | CTD_human |
| Hgene | GSTT1 | C2930617 | Pulmonary Fibrosis - from Asbestos Exposure | 1 | CTD_human |
| Hgene | GSTT1 | C3241937 | Nonalcoholic Steatohepatitis | 1 | CTD_human |
| Tgene | CYP3A5 | C0036341 | Schizophrenia | 3 | PSYGENET |
| Tgene | CYP3A5 | C0022658 | Kidney Diseases | 2 | CTD_human |
| Tgene | CYP3A5 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | CYP3A5 | C0040053 | Thrombosis | 1 | CTD_human |
| Tgene | CYP3A5 | C0087086 | Thrombus | 1 | CTD_human |
| Tgene | CYP3A5 | C0149504 | Encephalopathy, Toxic | 1 | CTD_human |
| Tgene | CYP3A5 | C0154659 | Toxic Encephalitis | 1 | CTD_human |
| Tgene | CYP3A5 | C0235032 | Neurotoxicity Syndromes | 1 | CTD_human |
| Tgene | CYP3A5 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Tgene | CYP3A5 | C0809983 | Schizophrenia and related disorders | 1 | PSYGENET |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies